FDA “Drug Watch” Early Warnings Will Have Lasting Negative Effect, PhRMA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A “Drug Watch” listing can do lasting damage to a brand’s reputation based on inadequate data, PhRMA Chief Medical Officer Antony says. The PhRMA exec uses an “extreme” example to highlight his point: imagine “someone reporting that they had early information that you may be a child molester.”
You may also be interested in...
FDA Track Record In Risk Communication Raised As Key Sentinel Concern
FDA's ongoing challenges with effectively communicating the risks indicated by postmarket safety signals need to be resolved before the agency activates its Sentinel surveillance program, a number of participants said during a Dec. 16 FDA workshop
FDA Track Record In Risk Communication Raised As Key Sentinel Concern
FDA's ongoing challenges with effectively communicating the risks indicated by postmarket safety signals need to be resolved before the agency activates its Sentinel surveillance program, a number of participants said during a Dec. 16 FDA workshop
FDA List Of Potential Safety Signals Has 3 Pfizer Drugs, Echoes Drug Watch Site
FDA's quarterly report that lists potential signals of serious risks for drugs is similar in design to a program that the agency proposed and then withdrew following industry criticism